切换至 "中华医学电子期刊资源库"
高级检索
中华胸部外科电子杂志

中华胸部外科电子杂志 ›› 2020, Vol. 07 ›› Issue (01) : 1 -11. doi: 10.3877/cma.j.issn.2095-8773.2020.01.001

所属专题： 文献；

论著

非小细胞肺癌患者术中发现胸膜播散的预后分析
范力文1, 杨海堂1, 韩轲1, 姚烽1, 赵洋1, 高文1, 赵珩1,†()   
  1. 1. 200030　上海交通大学附属胸科医院胸外科
  • 收稿日期:2020-01-10 出版日期:2020-02-28
  • 通信作者: 赵珩

Prognosis of surgery in the treatment of non-small cell lung cancer with unexpected pleural dissemination

Liwen Fan1, Haitang Yang1, Ke Han1, Feng Yao1, Yang Zhao1, Wen Gao1, Heng Zhao1,†()   

  1. 1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
  • Received:2020-01-10 Published:2020-02-28
  • Corresponding author: Heng Zhao
  • About author:
    Corresponding author: Zhao Heng, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

范力文, 杨海堂, 韩轲, 姚烽, 赵洋, 高文, 赵珩. 非小细胞肺癌患者术中发现胸膜播散的预后分析[J/OL]. 中华胸部外科电子杂志, 2020, 07(01): 1-11.

Liwen Fan, Haitang Yang, Ke Han, Feng Yao, Yang Zhao, Wen Gao, Heng Zhao. Prognosis of surgery in the treatment of non-small cell lung cancer with unexpected pleural dissemination[J/OL]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2020, 07(01): 1-11.

目的

评估手术切除肿瘤对非小细胞肺癌(NSCLC)伴恶性胸膜播散患者预后的影响。

方法

收集2011年1月至2015年12月上海市胸科医院NSCLC手术患者的临床资料，将术中意外发现胸膜播散的患者纳入研究。

结果

通过术中或术后病理学检查，共有160例NSCLC患者被诊断为胸膜播散。71例(44.4%)仅行胸膜结节活检(活检组)，89例(55.6%)行原发肿瘤切除术(切除组)。中位无进展生存期(PFS)和总生存期OS)分别为13个月和41个月，3、5年的无进展生存率分别为13.1%和5.7%，总生存率分别为56.0%和28.7%。切除组患者的PFS和OS均明显优于活检组(19个月vs 10个月，P＝0.000；48个月vs 33个月，P＝0.000)。切除组的3、5年无进展生存率和总生存率均高于活检组(20.8% vs 3.2%，10.8% vs 0；67.8% vs 41.0%，37.7% vs 18.2%)。接受亚肺叶切除术与肺叶切除术患者的生存差异无统计学意义(P＝0.34)。单因素和多因素分析结果显示：辅助靶向治疗、无恶性胸腔积液、T1/T2期和N0期是独立的预后因素。

结论

术中诊断为NSCLC伴胸膜播散的患者可通过手术切除原发肿瘤和包括靶向治疗在内的多学科治疗获益。辅助靶向治疗、无恶性胸腔积液、低T分期、低N分期患者的预后较好。在可行的情况下，楔形切除术可能是一个合适的选择，虽然不同手术方式亚组的预后差异无统计学意义，但其创伤更小。

关键词: 胸膜播散, 非小细胞肺癌, 手术治疗, 预后
Objective

To evaluate the effect of surgical resection on the prognosis of non-small cell lung cancer (NSCLC) patients with malignant pleural dissemination (PD).

Methods

Clinical data of consecutive patients who underwent surgeries for NSCLC between January 2011 and December 2015 at Shanghai Chest Hospital were collected. The patients who were found unexpected PD intraoperatively were enrolled in this study.

Results

A total of 160 patients diagnosed with unexpected malignant PD through intraoperatively or postoperatively histological examinations were enrolled in the present study. 71 (44.4%) patients received pleural nodule biopsy only, and 89 (55.6%) received primary tumor resection. The median progression-free survival(PFS) and median overall survival (OS)were respectively 13 months and 41 months. The 3- and 5-year PFS and OS rates for all patients were 13.1%, 5.7% and 56.0%, 28.7%, respectively. In comparison, patients in the resection group had better PFS (19.0 months vs 10.0 months, P < 0.001) and OS (48.0 months vs 33.0 months, P < 0.001) than those in the biopsy group. The 3- and 5-year PFS rates of resection group were higher than biopsy group (20.8% vs 3.2%, 10.8% vs 0). Similar results were found for OS rates(67.8% vs 41.0%, 37.7% vs 18.2%). There was no significant difference in survival between patients with sublobectomy and lobectomy (P = 0.34). Univariate and multivariate analyses showed that adjuvant targeted therapy, absence of malignant pleural effusion (MPE), stage T1/T2, and stage N0 were independent prognostic factors.

Conclusions

NSCLC patients with malignant pleural dissemination diagnosed intraoperatively may be beneficial from surgical resection of main tumor and multidisciplinary adjuvant therapy, especially targeted therapy. Patients with adjuvant targeted therapy, no MPE, lower T stage, and lower N stage may have a better prognosis. Wedge resection tends to be a proper choice if feasible, although there is no difference in survival among different types of resection.

Key words: Pleural dissemination, Non-small cell lung cancer, Surgery, Prognosis
表1 纳入患者的临床资料及分组比较
参数 总体(n＝160) 活检组(n＝71) 切除组(n＝89) P值
平均年龄(岁，±s) 57.1±9.8 57.9±9.2 56.6±10.2 (30-75) 0.39
性别[n(%)] ? ? ? 0.34
? 男性 87 (54.4) 36 (50.7) 51 (57.3) ?
? 女性 73 (45.6) 35 (49.3) 38 (42.7) ?
肿瘤位置[n(%)] ? ? ? 0.77
? 右肺 98 (61.3) 43 (60.6) 55 (61.8) ?
? 左肺 62 (38.7) 28 (39.4) 34 (38.2) ?
吸烟史[n(%)] ? ? ? 0.89
? 是 54 (33.8) 24 (33.8) 30 (33.7) ?
? 否 106 (66.2) 47 (66.2) 59 (66.3) ?
PS [n(%)] ? ? ? 0.31
? 0分 127 (79.4) 54 (76.1) 73 (82.0) ?
? 1分 33 (20.6) 17 (23.9) 16 (18.0) ?
术前血清肿瘤标志物水平[n(%)] ? ? ? 0.002
? 正常 35 (21.9) 7 (9.9) 28 (31.5) ?
? 升高 102 (63.8) 48 (67.6) 54 (60.7) ?
? 未知 23 (14.3) 16 (22.5) 7 (7.8) ?
新辅助治疗[n(%)] ? ? ? 0.08
? 化疗 9 (5.6) 1 (1.4) 8 (9.0) ?
? 放疗 1 (0.6) 0 (0) 1 (1.1) ?
? 否 150 (93.8) 70 (98.6) 80 (89.9) ?
辅助化疗[n(%)] ? ? ? 0.58
? 是 148 (92.5) 67 (94.4) 81 (91.0) ?
? 否 12 (7.5) 4 (5.6) 8 (9.0) ?
靶向治疗[n(%)] ? ? ? 0.11
? 是 90 (56.3) 35 (49.3) 55 (61.8) ?
? 否 57 (35.6) 27 (38.0) 30 (33.7) ?
? 未知 13 (8.1) 9 (12.7) 4 (4.5) ?
放疗[n(%)] ? ? ? 0.15
? 是 53 (33.1) 21 (29.6) 32 (36.0) ?
? 否 76 (47.5) 33 (46.5) 43 (48.3) ?
? 未知 31 (19.4) 17 (23.9) 14 (15.7) ?
表2 手术情况、病理学检测结果及分组资料比较
参数 总体(n＝160) 活检组(n＝71) 切除组(n＝89) P值
手术方式[n(%)] ? ? ? <0.001
? 仅活检 ? 71 (100.0) 0 (0) ?
? 亚肺叶切除 ? 0 (0) 42 (47.2) ?
? 肺叶切除 ? 0 (0) 41 (46.1) ?
? 扩大切除 ? 0 (0) 6 (6.7) ?
手术入路[n(%)] ? ? ? 0.060
? VATS 89 (55.6) 44 (62.0) 45 (50.6) ?
? 开胸手术 71 (44.4) 27 (38.0) 44 (49.4) ?
淋巴结切除方式[n(%)] ? ? ? <0.001
? 无 97 (60.6) 61 (85.9) 36 (40.4) ?
? 淋巴结采样 23 (14.4) 10 (14.1) 13 (14.7) ?
? 系统性淋巴结清扫 40 (25.0) 0 (0) 40 (44.9) ?
手术时间(min，±s) 82.3±37.0 66.3±25.1 95.3±39.7 <0.001
术中出血[n(%)] ? ? ? 0.002
? ≤100 mL 119 (74.4) 61 (85.9) 58 (65.2) ?
? >100 mL 41 (25.6) 10 (14.1) 31 (34.8) ?
术后住院时间(d，±s) 5.7±3.2 5.1±3.6 6.4±2.6 0.008
病理类型[n(%)] ? ? ? 0.130
? 腺癌 137 (85.6) 58 (81.7) 79 (88.8) ?
? 其他 23 (14.4) 13 (18.3) 10 (11.2) ?
肿瘤大小(cm，±s) 3.4±1.5 3.8±1.5 3.1±1.5 0.004
MPE[n(%)] ? ? ? <0.001
? 是 29 (18.1) 20 (28.2) 9 (10.1) ?
? 否 131 (81.9) 51 (71.8) 80 (89.9) ?
MPN[n(%)] ? ? ? <0.001
? 局限性 35 (21.9) 5 (7.0) 30 (33.7) ?
? 弥漫性 119 (74.4) 63 (88.7) 56 (62.9) ?
? 否 6 (3.7) 3 (4.3) 3 (3.4) ?
最佳T分期[n(%)] ? ? ? 0.330
? T1 11 (6.8) 2 (2.8) 9 (10.1) ?
? T2 82 (51.3) 34 (47.9) 48 (53.9) ?
? T3 28 (17.5) 14 (19.7) 14 (15.7) ?
? T4 35 (21.9) 17 (23.9) 18 (20.2) ?
? Tx 4 (2.5) 4 (5.7) 0 (0) ?
最佳N分期[n(%)] ? ? ? <0.001
? N0 45 (28.1) 10 (14.1) 35 (39.3) ?
? N1 33 (20.6) 18 (25.4) 15 (16.9) ?
? N2 69 (43.1) 33 (46.5) 36 (40.4) ?
? N3 7 (4.4) 6 (8.4) 1 (1.1) ?
? Nx 6 (3.8) 4 (5.6) 2 (2.3) ?
图1 切除组与活检组术后总生存率比较
图2 切除组与活检组术后无进展生存率比较
表3 预后因素的单因素分析
参数 PFS _OS
HR (95%CI) P值 HR (95%CI) P值
年龄 ? ? ? ?
? ≤59岁vs >59岁 0.910 (0.661～1.252) 0.561 0.625 (0.427～0.916) 0.015
性别 ? ? ? ?
? 男性vs女性 1.118 (0.813～1.538) 0.493 1.146 (0.783～1.678) 0.482
吸烟史 ? ? ? ?
? 否vs是 0.921 (0.661～1.283) 0.626 0.927 (0.628～1.368) 0.702
体力评分 ? ? ? ?
? 0 vs 1 0.578 (0.398～0.840) 0.004 0.493 (0.321～0.760) 0.001
术前血清肿瘤标志物水平 ? ? ? ?
? 正常vs升高 0.795 (0.526～1.202) 0.276 0.508 (0.298～0.867) 0.011
肿瘤位置 ? ? ? ?
? 左肺vs右肺 0.908 (0.655～1.258) 0.561 1.126 (0.766～1.654) 0.545
辅助化疗 ? ? ? ?
? 是vs否 0.446 (0.241～0.825) 0.008 0.493 (0.216～1.125) 0.086
辅助靶向治疗 ? ? ? ?
? 否vs是 1.209 (0.852～1.716) 0.287 2.404 (1.582～3.654) 0.000
EGFR突变 ? ? ? ?
? 否vs是 1.189 (0.789～1.790) 0.408 2.074 (1.227～3.508) 0.005
原发肿瘤切除 ? ? ? ?
? 否vs是 2.094 (1.503～2.919) 0.000 2.183 (1.488～3.203) 0.000
肿瘤大小 ? ? ? ?
? >3 cm vs ≤3 cm 1.864 (1.319～2.633) 0.000 2.165 (1.410～3.325) 0.000
MPE ? ? ? ?
? 否vs是 0.424 (0.285～0.632) 0.000 0.362 (0.236～0.554) 0.000
MPN ? ? ? ?
? 局限性vs弥漫性 0.824 (0.554～1.227) 0.340 1.000 (0.632～1.582) 1.000
病理类型 ? ? ? ?
? 腺癌vs其他 0.657 (0.416～1.036) 0.068 0.651 (0.391～1.083) 0.096
最佳N分期 ? ? ? ?
? N0 vs N1/N2/N3 0.468 (0.322～0.680) 0.000 0.367 (0.226～0.595) 0.000
最佳T分期 ? ? ? ?
? T1/T2 vs T3/T4 0.590 (0.423～0.822) 0.002 0.582 (0.396～0.857) 0.005
表4 预后因素的多因素分析
参数 PFS OS
HR (95%CI) P值 HR (95%CI) P值
年龄 ? ? ? ?
? ≤59岁vs >59岁 ? ? 0.570 (0.281～1.153) 0.118
PS ? ? ? ?
? 0 vs 1 0.747 (0.497～1.123) 0.160 0.597 (0.287～1.241) 0.167
术前血清肿瘤标志物水平 ? ? ? ?
? 正常vs升高 ? ? 0.779 (0.367～1.651) 0.514
辅助化疗 ? ? ? ?
? 是vs否 0.453 (0.229～0.897) 0.023 ? ?
辅助靶向治疗 ? ? ? ?
? 否vs是 ? ? 2.465 (1.061～5.729) 0.036
EGFR突变 ? ? ? ?
? 否vs是 ? ? 2.146 (0.961～4.793) 0.063
原发肿瘤切除 ? ? ? ?
? 否vs是 1.519 (1.049～2.201) 0.027 1.036 (0.491～2.187) 0.925
肿瘤大小 ? ? ? ?
? >3 cm vs ≤3 cm 1.516 (1.058～2.173) 0.023 1.704 (0.847～3.426) 0.135
MPE ? ? ? ?
? 否vs是 0.541 (0.344～0.849) 0.008 0.365 (0.170～0.783) 0.010
最佳N分期 ? ? ? ?
? N0 vs N1/N2/N3 0.617 (0.414～0.920) 0.018 0.339 (0.145～0.792) 0.012
最佳T分期 ? ? ? ?
? T1/T2 vs T3/T4 0.688 (0.482～0.981) 0.039 0.477 (0.232～0.982) 0.045
[1]
Ettinger D S, Wood D E, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020[J]. J Natl Compr Canc Netw, 2019, 17(12): 1464-1472.
[2]
Okamoto T, Iwata T, Mizobuchi T, et al. Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy[J]. Eur J Cardiothorac Surg, 2012, 41(1): 25-30.
[3]
Ou S H, Zell J A. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23，583 patients in the California Cancer Registry[J]. J Thorac Oncol, 2008, 3(3): 216-227.
[4]
Postmus P E, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer[J]. J Thorac Oncol, 2007, 2(8): 686-693.
[5]
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours[J]. J Thorac Oncol, 2007, 2(8): 706-714.
[6]
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51.
[7]
Li C, Kuo S W, Hsu H H, et al. Lung adenocarcinoma with intraoperatively diagnosed pleural seeding: Is main tumor resection beneficial for prognosis？[J]. J Thorac Cardiovasc Surg, 2018, 155(3): 1238-1249.
[8]
Iida T, Shiba M, Yoshino I, et al. Surgical intervention for non-small-cell lung cancer patients with pleural carcinomatosis: Results from the Japanese lung cancer registry in 2004[J]. J Thorac Oncol, 2015, 10(7): 1076-1082.
[9]
Sanchez de Cos Escuin J, Abal Arca J, Melchor Iniguez R, et al. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors[J]. Lung Cancer, 2014, 84(2): 182-189.
[10]
Ren Y, Dai C, Shen J, et al. The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected[J]. Oncotarget, 2016, 7(18): 26856-26865.
[11]
Yun J K, Kim M A, Choi C M, et al. Surgical outcomes after pulmonary resection for non-small cell lung cancer with localized pleural seeding first detected during surgery[J]. Thorac Cardiovasc Surg, 2018, 66(2)：142-149.
[12]
Mordant P, Arame A, Foucault C, et al. Surgery for metastatic pleural extension of non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2011, 40(6): 1444-1449.
[13]
Paul S, Sedrakyan A, Chiu YL, et al. Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database[J]. Eur J Cardiothorac Surg, 2013, 43(4): 813-817.
[14]
Zhong WZ, Li W, Yang XN, et al. Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis[J]. J Thorac Dis, 2015, 7(7): 1205-1212.
[15]
Shen H, Cao Y, Li X, et al. Surgical intervention improves survival for metastatic non-small cell lung cancer patients[J]. Medicine (Baltimore), 2016, 95(21): e3800.
[16]
Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2015, 10(11): 1515-1522.
[17]
Liu T, Liu H, Wang G, et al. Survival of M1a non-small cell lung cancer treated surgically: A retrospective single-center study[J]. Thorac Cardiovasc Surg, 2015, 63(7): 577-582.
[18]
Ren YJ, She YL, Dai CY, et al. Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination[J]. Interact Cardiovasc Thorac Surg, 2016, 22(3): 321-326.
[19]
Go T, Misaki N, Matsuura N, et al. Role of surgery in multi-modality treatment for carcinomatous pleuritis in patients with non-small cell lung cancer[J]. Surg Today, 2015, 45(2): 197-202.
[20]
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21): 2129-2139.
[21]
Sawabata N, Matsumura A, Motohiro A, et al. Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis[J]. Ann Thorac Surg, 2002, 73(2): 412-415.
[22]
Ohta Y, Tanaka Y, Hara T, et al. Clinicopathological and biological assessment of lung cancers with pleural dissemination[J]. Ann Thorac Surg, 2000, 69(4): 1025-1029.
[23]
Xu Y, Chen N, Wang Z, et al. Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation-a systemic review and meta-analysis[J]. J Thorac Dis, 2016, 8(10): 2843-2852.
[24]
Li S, Zhang S, Huang M, et al. Management of occult malignant pleural disease firstly detected at thoracotomy for non-small cell lung cancer patients[J]. J Thorac Dis, 2017, 9(10): 3851-3858.
[25]
Ichinose Y, Tsuchiya R, Koike T, et al. Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease[J]. Lung Cancer, 2001, 32(1): 55-60.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号